tbuckley/cabot-search huggingface dataset:
Conjunctivitis
Authors: M HINGORANI
Journal: Allergy (2006)

Deer keds (elk fly) have not previously been described as a cause of respiratory or conjunctival sensitization.To report a case of IgE-mediated allergic rhinoconjunctivitis from occupational exposure to deer ked.Skin prick testing (SPT) was performed with pollens, animal danders, mites, molds, and deer ked. The serum deer ked-specific IgE level was examined in ImmunoSpot and radioallergosorbent test assays, and deer ked IgE-binding fractions and their specificities were examined in immunoblot and immunoblot inhibition assays. Nasal provocation testing (NPT) and conjunctival provocation testing (CPT) were performed to detect the association between deer ked sensitization and rhinoconjunctival symptoms. Both SPT and NPT were performed with deer ked whole-body extract, whereas CPT was performed with deer ked wing.The results of SPT, NPT, and CPT were positive for deer ked. In laboratory tests, serum deer ked-specific IgE antibodies were demonstrated in radioallergosorbent test and ImmunoSpot assays. In immunoblot, IgE-binding bands were demonstrated at 17, 33, 70, and 85 kDa, which were clearly inhibited with deer ked extract but not with the control extract.Occupational IgE-mediated rhinoconjunctival allergy to deer ked was confirmed in this patient.
Alloreactivity as a Source of High Avidity T Cell Clones Specific for Cancer Testis-Antigens Associated with Multiple Myeloma: Prospects for Adoptive Immunotherapy with Primary T Cells Redirected toward Multiple Myeloma by T Cell Receptor Gene Transfer.
Authors: Holger Kronig, Kathrin Hofer, Julia Neudorfer, Christian Peschel, Helga Bernhard
Journal: Blood (2006)
Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([18F] FDG-PET/CT) in Aggressive T-Cell Lymphomas
Authors: Xavier Cahu, Caroline Bodet-Milin, Thomas Gastinne, Hervé Maisonneuve, Nadine Morineau, Gandhi Damaj, Philippe Solal-Celigny, Philippe Moreau, Henri Jardel, Philippe Moreau, Jean-Luc Harousseau, Françoise Kraeber-Bodéré, Steven Le Gouill
Journal: Blood (2008)
First Results of Russian Multicenter Population Base Study of the Incidence of Chronic Myeloid Leukemia
Authors: Sergey M. Kulikov, Olga Yu. Vinogradova, Ekaterina Yu. Chelysheva, Marya V. Galayko, Irina A. Titshenko, Eduard G. Gendgan, Olga M. Senderova, Valentyna M. Pepelyaeva, Sergey V. Meresy, Alexander S. Luchinin, Vanik A. Ovsepyan, Galina I. Milutina, Lubov V. Gavrilova, Ludmila B. Avdeeva, Anna G. Turkina
Journal: Blood (2012)
Phase I/II Study of Clofarabine Combined with Standard Dose Cytarabine as Remission Induction Therapy of De Novo AML in Elderly Patients ≥60 Years.
Authors: James M. Foran, Angeline S. The, Marcel Devetten, Sreelatha Meleth, Jeff Worrell, Pam Dixon, Mikkael A. Sekeres
Journal: Blood (2005)
Prediagnostic Thrombocytosis Increases the Risk of Advanced Gynecological Cancer and Increases Mortality Independently of Cancer Stage – a Population-Based Study
Authors: Christen Lykkegaard Andersen, Volkert Siersma, Hans Carl Hasselbalch, Ole Weis Bjerrum, Peter Felding, Bent Lind, Jan Palmblad, Niels de Fine Olivarius
Journal: Blood (2014)
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines
Authors: Frederika A. van Nimwegen, Georgios Ntentas, Sarah C. Darby, Michael Schaapveld, Michael Hauptmann, Pieternella J. Lugtenburg, Cecile P. M. Janus, Laurien Daniels, Flora E. van Leeuwen, David J. Cutter, Berthe M. P. Aleman
Journal: Blood (2017)
Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
Authors: Animesh Pardanani, Jason Gotlib, Vikas Gupta, Andrew W. Roberts, Martha Wadleigh, Shireen Sirhan, Linda M Bavisotto, Jun Kawashima, Mark Kowalski, Ayalew Tefferi
Journal: Blood (2012)
The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia.
Authors: Lars Klemm, Cihangir Duy, Ilaria Iacobucci, Gregor von Levetzow, Niklas Feldhahn, Yong-mi Kim, Wolf-Karsten Hofmann, Hassan Jumaa, John Groffen, Nora Heisterkamp, Giovanni Martinelli, Michael R Lieber, Rafael Casellas, Markus Müschen
Journal: Blood (2009)
Novel Putative Polymorphism in SERPINC1 Encoding Antithrombin III Is Implicated in Elevated Estimated Systolic Pulmonary Pressure in Patients with Chuvash Polycythemia.
Authors: Victor R. Gordeuk, Xu Zhang, Wei Zhang, Shwu-Fan Ma, Craig Sable, Galina Miasniakova, Adelina Sergueeva, Tatiana Ammosova, Min Xu, Sergei Nekhai, Josef T. Prchal, Michael Wade, Joe GN Garcia, Roberto Machado
Journal: Blood (2012)
AF1q Is a Novel Poor Prognostic Marker for Adult Acute Myelogenous Leukemia (AML) Patients with Normal Cytogenetics.
Authors: Crawford J. Strunk, Uwe Platzbecker, Christian Thiede, Markus Andreas Schaich, Thomas Illmer, Zizhen Kang, Patrick Leahy, Chunbiao Li, Sunee Reiner, Mary J. Laughlin, Hillard M. Lazarus, Kevin D. Bunting, Stanton L. Gerson, Gerhard Ehninger, William W. Tse
Journal: Blood (2005)
Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles
Authors: Mohammad-Ali Shahbazi, Patrick Vingadas Almeida, Alexandra Correia, Barbara Herranz-Blanco, Neha Shrestha, Ermei Mäkilä, Jarno Salonen, Jouni Hirvonen, Hélder A. Santos
Journal: Journal of Controlled Release (2017)
Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000–2014
Authors: J. Craig Nelson, Daniel A. Spyker
Journal: American Journal of Psychiatry (2017)

The authors sought to determine the relative morbidity and mortality associated with drugs used to treat depression and to examine specific clinical effects associated with serious outcomes.The National Poison Data System, which receives exposure reports from regional poison centers serving the United States, Puerto Rico, and the District of Columbia, was queried for single drug exposures in individuals 12 years and older during the period 2000-2014. Medications included were antidepressants, atypical antipsychotics, anticonvulsants, lithium, and other medications used in the treatment of depression. The main outcomes were the morbidity index (the number of serious outcomes per 1,000 exposures) and the mortality index (the number of fatal outcomes per 10,000 exposures).During this 15-year period, there were 962,222 single substance exposures to the 48 medications studied. Serious outcomes rose 2.26-fold and in linear fashion over the 15 years. While tricyclic and monoamine oxidase inhibitor medications were associated with high morbidity and mortality, several newer agents also appeared hazardous. Lithium, quetiapine, olanzapine, bupropion, and carbamazepine were associated with high morbidity indices. Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasidone, valproic acid, carbamazepine, and citalopram were associated with higher mortality indices.Serious outcomes after overdose or nonintentional exposures to medications used to treat depression have risen dramatically over the past 15 years. The present data suggest that the morbidity and mortality risks vary substantially among these medications. These differences become important when selecting treatments for patients with depression, especially those at increased risk for suicide.
Coronary Angiography and Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest—Reply
Authors: Nish Patel, Nileshkumar J. Patel, Mauricio G. Cohen
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Microtubule-interacting agents increase cell surface expression of human leukocyte antigen class i molecules in ovarian cancer cells
Authors: Mohamed Borghan, Gary Goldberg, Shahabi Shohreh
Journal: Cancer Research (2008)

LB-126  Background: Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Standard first line chemotherapy for ovarian cancer includes taxane and platin based agents. Taxol stabilizes microtubules and arrests cells in the G2/M phase of the cell cycle. Little is known about the effect of microtubule-interacting (stabilizing and destabilizing) agents on the immune responses to tumors. There is compelling evidence that cancer cells use multiple strategies to evade immune recognition. One of these mechanisms is the down-regulation of human leukocyte antigen (HLA) Class I molecule expression on the tumor cell surface, allowing the cancer cells to escape immune recognition and destruction. Objective: To evaluate the effect of microtubule-interacting agents on HLA class I molecule expression in ovarian cancer cells. Methods: The IC50 was determined for microtubule-stabilizing agents (Taxol and Epothilone B), microtubule-destabilizing agents (Vinblastine and Navelbine), and alkalyting agents (Cisplatin and Carboplatin) using ovarian cancer cell line, HEY. Cells were treated with different concentrations of each agent, ranging from 1-fold IC50 to 50-fold IC50, and incubated at 37°C for 24 h, 48 h and 72 h. Cell surface expression of HLA Class I molecules (A, B, and C) was examined by flow cytometry using anti-HLA-A,-B,-C antibody, G46-2.6 clone. Results: Taxol, Epothilone B, and Vinblastine had comparable low nanomolar values of IC50 (1 to 3 nM). The IC50 of Cisplatin and Carboplatin was 10 μM and 700 μM, respectively. The Microtubule-stabilizing agents (Taxol and Epothilone B) and the microtubule-destabilizing agents (Vinblastine and Vinorelbine) all increased the cell surface expression of HLA Class I molecules in HEY cells. The increase of HLA Class I molecule expression was dose- and time-dependent. The gradual increase of HLA Class I molecule expression was observed after treatment with 10-fold to 50-fold IC50 of the drugs for 48 to 72 h. Both the microtubule stabilizing and the destabilizing agents increased the cell surface expression of HLA to similar levels, 2-fold (P = 0.002). Cisplatin and Carboplatin had no effect on the expression of HLA Class I molecules. Conclusions: Low nanomolar concentrations of microtubule-destabilizing and microtubule-stabilizing agents increase the expression of HLA Class I molecules in the ovarian cancer cell line, HEY. Our data suggest that low doses of microtubule-interacting agents can mediate the modulation of cell surface HLA expression and consequently may enhance immune recognition of tumor cells.
CD72 Expression Patterns in ZAP70 Positive and Negative Chronic Lymphocytic Leukemia: Potential Regulatory Role in BCR Signalling
Authors: Francisco P. Careta, Rodrigo A. Panepucci, Daniel M Matos, Rodrigo Proto-Siqueira, Wilson A. Silva-Junior, Amelia G Araujo, Aglair B Garcia, Roberto P. Falcao, Marco A Zago
Journal: Blood (2008)
Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors
Authors: Vivien Mak, Joseph M. Connors, Richard Klasa, Laurie H. Sehn, Diego Villa, Tamara Shenkier, Mukesh Chhanabhai, Randy D. Gascoyne, Kerry J. Savage
Journal: Blood (2011)
Efficacy of Conventional Cytogenetics and FISH for EGR1 To Detect Deletion 5q in Hematological Disorders and To Assess Response to Treatment with Lenalidomide.
Authors: Ying Zou, Stephanie Fink, Kimberly Stockero, Sarah Paternoster, Stephanie Smoley, Han Tun, Craig Reeder, Ayalew Tefferi, Gordon Dewald
Journal: Blood (2006)
The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies
Authors: Jan A. Burger, Susan O'Brien, Nathan Fowler, Ranjana Advani, Jeff Porte Sharman, Richard R. Furman, Raquel Izumi, Joseph Buggy, David Loury, Ahmed Hamdy, John C. Byrd, Kristie A. Blum
Journal: Blood (2010)
Inhibition of TACE Activity Enhances the Susceptibility of Myeloma Cells to TRAIL.
Authors: Kumiko Kagawa, Masahiro Abe, Shiro Fujii, Osamu Tanaka, Ai Mihara, Shingen Nakamura, Kazuhiro Miki, Jin Asano, Kyoko Takeuchi, Kenichiro Yata, Toshihiro Hashimoto, Shuji Ozaki, Masahiro Hiasa, Toshio Matsumoto
Journal: Blood (2007)
Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.
Authors: Alexandra Boehm, Karl J. Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, Sophia Derdak, Winfried F. Pickl, Puchit Samorapoompichit, Christian Sillaber, Stefan Florian, Karoline Sonneck, Wolfgang R. Sperr, Peter Valent
Journal: Blood (2004)
Not even wrong: The “it's just X” fallacy
Authors: Gary Lupyan
Journal: Behavioral and Brain Sciences (2016)

Abstract I applaud Firestone &amp; Scholl (F&amp;S) in calling for more rigor. But, although F&amp;S are correct that some published work on top-down effects suffers from confounds, their sweeping claim that there are no top-down effects on perception is premised on incorrect assumptions. F&amp;S's thesis is wrong. Perception is richly and interestingly influenced by cognition.
Revised Framingham Stroke Risk Profile to Reflect Temporal Trends
Authors: Carole Dufouil, Alexa Beiser, Leslie A. McLure, Philip A. Wolf, Christophe Tzourio, Virginia J. Howard, Andrew J. Westwood, Jayandra J. Himali, Lisa Sullivan, Hugo J. Aparicio, Margaret Kelly-Hayes, Karen Ritchie, Carlos S. Kase, Aleksandra Pikula, Jose R. Romero, Ralph B. D’Agostino, Cécilia Samieri, Ramachandran S. Vasan, Genevieve Chêne, George Howard, Sudha Seshadri
Journal: Circulation (2017)

Age-adjusted stroke incidence has decreased over the past 50 years, likely as a result of changes in the prevalence and impact of various stroke risk factors. An updated version of the Framingham Stroke Risk Profile (FSRP) might better predict current risks in the FHS (Framingham Heart Study) and other cohorts. We compared the accuracy of the standard (old) and of a revised (new) version of the FSRP in predicting the risk of all-stroke and ischemic stroke and validated this new FSRP in 2 external cohorts, the 3C (3 Cities) and REGARDS (Reasons for Geographic and Racial Differences in Stroke) studies. We computed the old FSRP as originally described and a new model that used the most recent epoch-specific risk factor prevalence and hazard ratios for individuals ≥55 years of age and for the subsample ≥65 years of age (to match the age range in REGARDS and 3C studies, respectively) and compared the efficacy of these models in predicting 5- and 10-year stroke risks. The new FSRP was a better predictor of current stroke risks in all 3 samples than the old FSRP (calibration χ2 of new/old FSRP: in men: 64.0/12.1, 59.4/30.6, and 20.7/12.5; in women: 42.5/4.1, 115.4/90.3, and 9.8/6.5 in FHS, REGARDS, and 3C, respectively). In the REGARDS, the new FSRP was a better predictor among whites compared with blacks. A more contemporaneous, new FSRP better predicts current risks in 3 large community samples and could serve as the basis for examining geographic and racial differences in stroke risk and the incremental diagnostic utility of novel stroke risk factors.
Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke
Authors: Xiaoming Hu, T. Michael De Silva, Jun Chen, Frank M. Faraci
Journal: Circulation Research (2017)

The consequences of cerebrovascular disease are among the leading health issues worldwide. Large and small cerebral vessel disease can trigger stroke and contribute to the vascular component of other forms of neurological dysfunction and degeneration. Both forms of vascular disease are driven by diverse risk factors, with hypertension as the leading contributor. Despite the importance of neurovascular disease and subsequent injury after ischemic events, fundamental knowledge in these areas lag behind our current understanding of neuroprotection and vascular biology in general. The goal of this review is to address select key structural and functional changes in the vasculature that promote hypoperfusion and ischemia, while also affecting the extent of injury and effectiveness of therapy. In addition, as damage to the blood-brain barrier is one of the major consequences of ischemia, we discuss cellular and molecular mechanisms underlying ischemia-induced changes in blood-brain barrier integrity and function, including alterations in endothelial cells and the contribution of pericytes, immune cells, and matrix metalloproteinases. Identification of cell types, pathways, and molecules that control vascular changes before and after ischemia may result in novel approaches to slow the progression of cerebrovascular disease and lessen both the frequency and impact of ischemic events.
Gaining knowledge mediates changes in perception (without differences in attention): A case for perceptual learning
Authors: Lauren L Emberson
Journal: Behavioral and Brain Sciences (2016)

Abstract Firestone &amp; Scholl (F&amp;S) assert that perceptual learning is not a top-down effect, because experience-mediated changes arise from familiarity with the features of the object through simple repetition and not knowledge about the environment. Emberson and Amso (2012) provide a clear example of perceptual learning that bypasses the authors' “pitfalls” and in which knowledge, not repeated experience, results in changes in perception.
High-Dose Therapy with Peripheral Blood Stem Cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and Correlation with the ISS-Score
Authors: Kai Neben, Anna Jauch, Dirk Hose, Friedrich Cremer, Christiane Heiss, Thomas Hielscher, Uta Bertsch, Ulrike Klein, Jens Hillengass, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2008)
Superior Incidence of Progression-Free Survival (PFS) Following High- Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM) Patients Receiving Pre-Transplant Induction with IMiDs Versus Conventional VAD Induction Chemotherapy.
Authors: H. Kent Holland, Scott R. Solomon, Asad Bashey, Lawrence E. Morris
Journal: Blood (2008)
Patient reported outcomes in patients undergoing arthroscopic partial meniscectomy for traumatic or degenerative meniscal tears: comparative prospective cohort study
Authors: Jonas Bloch Thorlund, Martin Englund, Robin Christensen, Nis Nissen, Kenneth Pihl, Uffe Jørgensen, Jeppe Schjerning, L Stefan Lohmander
Journal: BMJ (2017)

<b>Objectives</b>&nbsp;To compare patient reported outcomes from before surgery to 52 weeks after surgery between individuals undergoing arthroscopic partial meniscectomy for traumatic meniscal tears and those for degenerative meniscal tears. <b>Design</b>&nbsp;Comparative prospective cohort study. <b>Setting</b>&nbsp;Four public orthopaedic departments in the Region of Southern Denmark. Participants were recruited between 1 February 2013 and 31 January 2014, and at one of the original four hospitals from 1 February 2014 to 31 January 2015. <b>Participants</b>&nbsp;Individuals selected from Knee Arthroscopy Cohort Southern Denmark, aged 18-55, and undergoing arthroscopic partial meniscectomy for a traumatic or degenerative meniscal tear (defined by a combination of age and symptom onset). <b>Interventions</b>&nbsp;Both participant groups underwent arthroscopic partial meniscectomy for a meniscal tear, with operating surgeons recording relevant information on knee pathology. Patient reported outcomes were recorded via online questionnaires. <b>Main outcome measures</b>&nbsp;Primary outcome was the average between-group difference in change on four of five subscales of the knee injury and osteoarthritis outcome score (KOOS). The four subscales covered pain, symptoms, sport and recreational function, and quality of life (KOOS<sub>4</sub>). A 95% confidence interval excluding differences greater than 10 KOOS points between groups was interpreted as absence of a clinically meaningful difference. Analyses adjusted for age, sex, and body mass index. <b>Results</b>&nbsp;397 eligible adults (42% women) with a traumatic or degenerative meniscal tear (n=141, mean age 38.7 years (standard deviation 10.9); n=256, 46.6 years (6.4); respectively) were included in the main analysis. At 52 weeks after arthroscopic partial meniscectomy, 55 (14%) patients were lost to follow-up. Statistically, participants with degenerative meniscal tears had a significantly larger improvement in KOOS<sub>4</sub> scores than those with traumatic tears (adjusted between-group difference −5.1 (95% confidence interval −8.9 to −1.3); P=0.008). In the analysis including KOOS<sub>4</sub> score at all time points, a significant time-by-group interaction was observed in both the unadjusted (P=0.025) and adjusted analysis (P=0.024), indicating better self-reported outcomes in participants with degenerative tears. However, the difference between groups was at no time point considered clinically meaningful. <b>Conclusions</b>&nbsp;These results question the current tenet that patients with traumatic meniscal tears experience greater improvements in patient reported outcomes after arthroscopic partial meniscectomy than patients with degenerative tears. <b>Trial registration</b>&nbsp;ClinicalTrials.gov identifier NCT01871272.
A pathway from leukaemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. Accepted September 2012.
Authors: F. Griaud, A. Pierce, M.B. Gonzalez Sanchez, M. Scott, S.A. Abraham, T.L. Holyoake, D.D.H. Tran, T. Tamura, A.D. Whetton
Journal: Leukemia (2012)